Lisanti Capital Growth LLC Has $622,000 Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Lisanti Capital Growth LLC trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,310 shares of the company's stock after selling 88,830 shares during the period. Lisanti Capital Growth LLC's holdings in Dyne Therapeutics were worth $622,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 24.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,617 shares of the company's stock valued at $812,000 after acquiring an additional 5,696 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $810,000. Swiss National Bank raised its stake in shares of Dyne Therapeutics by 41.5% in the first quarter. Swiss National Bank now owns 85,200 shares of the company's stock worth $2,419,000 after purchasing an additional 25,000 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in Dyne Therapeutics during the 1st quarter worth $573,000. Finally, Sei Investments Co. bought a new stake in Dyne Therapeutics in the 1st quarter worth about $693,000. 96.68% of the stock is currently owned by institutional investors.

Insider Activity at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,390 shares of the business's stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares of the company's stock, valued at $3,405,524.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company's stock, valued at approximately $3,405,524.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the business's stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company's stock, valued at $8,533,929.15. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,975 shares of company stock valued at $5,693,789 in the last quarter. Insiders own 20.77% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Oppenheimer reiterated an "outperform" rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, Morgan Stanley lifted their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $50.60.

Dyne Therapeutics Price Performance

DYN stock traded up $1.20 during midday trading on Tuesday, hitting $29.33. The stock had a trading volume of 1,924,884 shares, compared to its average volume of 1,492,136. The firm has a market cap of $2.94 billion, a PE ratio of -8.45 and a beta of 1.10. Dyne Therapeutics, Inc. has a 12-month low of $8.05 and a 12-month high of $47.45. The company's 50-day moving average price is $32.69 and its 200 day moving average price is $35.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.